Replimune FY27 Q1 net loss narrows to $69.8 million; R&D expenses fall to $49.3 million

• Replimune posted a GAAP net loss of USD 69.8 million for fiscal Q1 ended June 30, 2026, narrowing from USD 86.7 million a year earlier.
• R&D expense fell to USD 49.3 million from USD 57.8 million, on lower personnel and direct research costs across IGNYTE, ARTACUS, CERPASS.
• Selling, general and administrative costs dropped to USD 19 million from USD 32.6 million, including USD 4.1 million of stock-based compensation.
• Cash, cash equivalents and short-term investments totaled USD 195.3 million at quarter-end; August equity issuance added USD 141 million net proceeds.
• FDA granted accelerated approval to TUDRIQEV with nivolumab in advanced melanoma; U.S. launch expected within 60 days, IGNYTE-3 readout targeted 2030.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140800PRIMZONEFULLFEED9810154) on August 14, 2026, and is solely responsible for the information contained therein.